8:45—9:00: Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide

doi:10.1016/S1095-0397(00)00056-X

Clinical Positron Imaging

Volume 3, Issue 4, July–August 2000, Page 144

https://doi.org/10.1016/S1095-0397(00)00056-X Get rights and content

Abstract

Assessing prostate metastases is difficult with conventional radiographic modalities as few patients have soft tissue involvement and most have only bone lesions. Even with FDG PET, problems due to decreased avidity compared to other tumor types can occur. We assessed PET's ability to monitor changes in such tumors during an anti-angiogenic therapy. We measured changes in tumor blood flow (¹⁵O), blood volume (¹¹CO), ¹⁸F-FDG uptake and “metabolic volume” before and during thalidomide treatment, to see if these changes correlated with changes in PSA values.

Six patients with androgen-independent prostate cancer were imaged with ¹⁸F-FDG, ¹¹CO, and ¹⁵O water before and during (mean interval 63 days, range 55-76 days) thalidomide therapy (200-1200mg/day). Lesions were visually identified on FDG images (9 bone, 5 soft tissue lesions). VOI's were generated by 3D region growing, with a 50% maximum pixel threshold. These VOI's were registered with, and applied to, the ¹¹CO and water studies. Correlations with PSA values were done using the Spearman rank test.

The change in maximum (r = 0.77, p = 0.06) and mean FDG value (r = 0.83, p = 0.03), functional FDG volume (r = 0.66, p = 0.14), and 11-CO blood volume (r = 0.77, p = 0.06) all correlated with the change in PSA. Changes in blood flow values were smaller than the variance of the method for repeated measures, likely due to low flow values in bone.

Changes in blood volume measured by ¹¹CO, and the mean and peak activity and functional volume measured by ¹⁸F-FDG, correlate with changes in PSA and may be useful in monitoring anti-angiogenic therapy in prostate cancer.

References (0)

Cited by (21)

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates
2013, Urologic Oncology: Seminars and Original Investigations
Citation Excerpt :
In current literature, very few papers from few patients under anti-androgenic therapy are reported. Preliminary results with 18F-FDG PET [61,62], 18F-FCH PET [63], and 11C-choline PET/CT [25] revealed a significant decrease of tracer uptake after initiation of anti-androgenic therapy. Giovacchini et al. (2008) monitored a group of 6 patients with localized prostate cancer of a median Gleason score equal to 6 (range 5–7) under bicalutamide treatment (150 mg/d) for a median time of 4 months (range 3–12 months) by 11C-choline PET/CT.
PET- and PET/CT using [¹¹C]- and [¹⁸F]-labeled choline derivates are increasingly being used for imaging of prostate cancer. The value of PET- and PET/CT with [¹¹C]- and [¹⁸F]-labeled choline derivates in biochemical recurrence of prostate cancer has been examined in many studies and demonstrates an increasing importance. PET/CT, in comparison to PET, improves especially the lesion localization as well as characterization. Primary prostate cancer can be detected with moderate sensitivity using PET and PET/CT using [¹¹C]- and [¹⁸F]-labeled choline derivates—the differentiation between benign prostatic hyperplasia, prostatitis, or high-grade intraepithelial neoplasia (HGPIN) is not always possible. At the present time, [¹¹C]-choline PET/CT is not recommended in the primary setting but may be utilized in clinically suspected prostate cancer with repeatedly negative prostate biopsies, in preparation of a focused re-biopsy. Promising results have been obtained for the use of PET and PET/CT with [¹¹C]- and [¹⁸F]-labeled choline derivates in patients with biochemical recurrence. The detection rate of choline PET and PET/CT for local, regional, and distant recurrence in patients with a biochemical recurrence shows a linear correlation with PSA value at the time of imaging and reaches about 75% in patients with PSA > 3 ng/ml. Even at PSA values below 1 ng/ml, the recurrence can be diagnosed with choline PET/CT in approximately one-third of the patients. PET and PET/CT with [¹¹C]- and [¹⁸F]-choline derivates can be helpful in the clinical setting for choosing a therapeutic strategy in the sense of an individualized treatment: an early diagnosis of recurrence is crucial to the choice of optimal treatment. Especially important for the choice of treatment is the exact localization of the site of recurrence: local recurrence, recurrence as lymph node metastasis, or systemic recurrence, as it has direct influence on individual therapy. This article reviews the use of PET and PET/CT with [¹¹C]- and [¹⁸F]-labeled choline derivates in prostate cancer imaging with special emphasis on patients with biochemical recurrence. We briefly provide an overview of PET tracers for prostate cancer imaging, the rationale of using choline derivatives for prostate cancer imaging and discuss the contribution of choline PET/CT in patients suffering from prostate cancer with an emphasis on recurrent disease. Furthermore, we provide an outlook on future prospects of choline PET/CT imaging for therapy guidance and monitoring in the framework of therapy individualization.
Thalidomide
2004, Lancet
Citation Excerpt :
However, dose escalation over 600 mg in this elderly cohort was rare. Improvements in measurable disease by bone scan and positron emission tomography114 were also noted in some responsive patients. In another study115 in men with androgen independent prostate cancer, thalidomide 100 mg per day resulted in a fall in prostate specific antigen in 15% of patients, with VEGF and basic fibroblast growth factor serum concentrations correlating with progression and favourable response, respectively.
Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer and inflammatory diseases. Although the evolution of its clinical application could not have been predicted from the tragedy associated with its misuse in the past, its history serves as a lesson in drug development that underscores the need to understand the molecular pharmacology of a compound's activity, including associated toxicities. Here, we summarise the applications for thalidomide with an emphasis on clinical trials published over the past 10 years, and consider our knowledge of the molecular pharmacology of the drug in the context of clinical trial data, attempting to provide a mechanism-guided understanding of its activity.
Anti-angiogenesis in cancer therapy
2003, Seminars in Oncology Nursing
To review tumor angiogenesis, identify potential targets for anti-angiogenic cancer therapy, and highlight certain anti-angiogenic agents in clinical trials.
Research articles, abstracts, review articles, and book chapters.
Tumor angiogenesis is a complex, multistep process that provides a target for antineoplastic therapy whereby tumor neovasculature is interrupted at various steps in the angiogenic process. Clinical trials are investigating the application and efficacy of anti-angiogenic agents.
Oncology nurses must continually increase their knowledge with the onset of newer, targeted agents. This will provide a background for educating and caring for the patient who is receiving anti-angiogenic therapy.
Current status of thalidomide and its role in the treatment of metastatic prostate cancer
2003, Critical Reviews in Oncology/Hematology
Following the discovery of its anti-angiogenic properties and despite its tragic history, thalidomide has re-surfaced in the field of oncology. Concurrent with its evaluation in various clinical trials for cancer, thalidomide's mechanism of action is sought and new analogues with improved efficacy and pharmacological profile are emerging. This review is a critical evaluation of thalidomide metabolism, molecular targets, anti-angiogenic activity and clinical efficacy with an emphasis on metastatic prostate cancer.
Angiogenesis and apoptosis
2003, Seminars in Cancer Biology
This review assembles the laboratory and clinical evidence that cytotoxic chemotherapy and antiangiogenic therapy are each dependent on endothelial cell apoptosis. During cytotoxic chemotherapy, apoptosis of endothelial cells in the vascular bed of tumors precedes apoptosis of tumor cells, even when the tumor has been made drug resistant. Administration of an angiogenesis inhibitor which is not directly cytotoxic to tumor cells can increase tumor cell apoptosis and inhibit tumor growth by inhibiting endothelial proliferation and migration and/or by inducing endothelial apoptosis. Furthermore, oncogene expression and loss of tumor suppressor gene activity can at once protect tumor cells against apoptosis and increase their angiogenic output. Both of these survival advantages conferred on the tumor can be overcome by antiangiogenic therapy. They can also be overcome by cytotoxic chemotherapy administered on a low dose ‘antiangiogenic schedule’ which continuously exposes endothelial cells in the tumor bed to the drug. As a result, endothelial apoptosis can be demonstrated to precede tumor cell apoptosis, and tumors regress or are inhibited, whether or not the tumor cells are resistant to the drug, and with little or no host toxicity. In contrast, cytotoxic chemotherapy administered on a ‘conventional schedule’ of maximal tolerated dose followed by an off-therapy interval, becomes ineffective after drug resistance is acquired.
On the basis of these experimental findings, chemotherapy of cancer may possibly be improved—i.e. decreased drug resistance and decreased toxic side-effects—by changing dose and schedule to maximize apoptosis of endothelial cells in the vascular bed of tumors. Further improvement may be achieved by combining angiogenesis inhibitors with ‘antiangiogenic chemotherapy’.
Erythrocytes labeled with [<sup>18</sup>F]SFB as an alternative to radioactive CO for quantification of blood volume with PET
2013, Contrast Media and Molecular Imaging

View all citing articles on Scopus

View full text

Scientific paper8:45—9:00: Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide

Abstract

Scientific paper
8:45—9:00: Using PET ¹⁸F-FDG, ¹¹CO, and ¹⁵O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide